Drug Profile


Alternative Names: AMO-02; NP-031112; NP-12; Nypta; Zentylor

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuropharma
  • Developer AMO Pharma; Noscira
  • Class Antidementias; Small molecules; Thiadiazoles
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Glycogen synthase kinase 3 inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy; Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myotonic dystrophy
  • Discontinued Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 27 Jul 2017 Tideglusib receives Orphan Drug status for Myotonic dystrophy in USA
  • 30 May 2017 Tideglusib receives Fast Track designation for Congenital Myotonic dystrophy [PO,Suspension] in USA
  • 10 Aug 2016 AMO Pharma announces intention to submit an IND to US FDA in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top